Forum Diabetologicum - Issue 2/2022
Editorial
76
82
Dabigatran in patients with diabetes mellitus and atrial fibrillation
Jakub Benko, Veronika Mikušová, Martin Jozef Péč, Tomáš Bolek, Matej Samoš, Marián Mokáň
87
Rivaroxaban in patients with diabetes mellitus and atrial fibrillation
Monika Péčová, Jakub Benko, Martin Jozef Péč, Tomáš Bolek, Juraj Sokol, Matej Samoš, Eva Hajtmanová, Ján Staško, Marián Mokáň
94
Apixaban in patients with diabetes mellitus and atrial fibrillation
Matej Samoš, Tomáš Bolek, Martin Jozef Péč, Marián Mokáň
98
Edoxaban in patients with diabetes mellitus and atrial fibrillation
Kristína Brisudová, Tomáš Bolek, Matej Samoš, Marián Mokáň
102
Laboratory monitoring of the treatment with direct oral anticoagulants
Lucia Stančiaková, Rid Škorňová, Jela Ivanková, Miroslava Dobrotová, Ivana Plameňová, Pavol Hollý, Tomáš Bolek, Matej Samoš, Peter Kubisz, Ján Staško
108
Bleeding in patients on direct oral anticoagulants therapy: diagnostic-therapeutic management
Tomáš Bolek, Matej Samoš, Jakub Benko, Jakub Jurica, Martin Jozef Péč, Marek Cingel, Marián Mokáň
113
Forum Diabetologicum
2022 Číslo 2
Najčítanejšie v tomto čísle
- Bleeding in patients on direct oral anticoagulants therapy: diagnostic-therapeutic management
- Rivaroxaban in patients with diabetes mellitus and atrial fibrillation
- Diabetes mellitus and atrial fibrillation
- Laboratory monitoring of the treatment with direct oral anticoagulants